These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9160695)

  • 1. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
    Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
    Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD31 mismatching affects marrow transplantation outcome.
    Grumet FC; Hiraki DD; Brown BWM ; Zehnder JL; Zacks ES; Draksharapu A; Parnes J; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(9):503-12. PubMed ID: 11669217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
    Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of leukemia with partially matched related bone marrow transplantation.
    Munn RK; Henslee-Downey PJ; Romond EH; Marciniak EJ; Fleming DR; Messino MJ; Macdonald JS; Rayens MK; Harder EJ; Phillips GL; Thompson JS
    Bone Marrow Transplant; 1997 Mar; 19(5):421-7. PubMed ID: 9052906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated donor marrow transplantation in children.
    Balduzzi A; Gooley T; Anasetti C; Sanders JE; Martin PJ; Petersdorf EW; Appelbaum FR; Buckner CD; Matthews D; Storb R; Sullivan KM; Hansen JA
    Blood; 1995 Oct; 86(8):3247-56. PubMed ID: 7579422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia.
    Chiang KY; Van Rhee F; Godder K; Bridges K; Adams S; Mehta J; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Mar; 27(5):507-10. PubMed ID: 11313684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
    Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
    Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors.
    Hasegawa W; Lipton JH; Messner HA; Jamal H; Yi QL; Daly AS; Kotchetkova N; Kiss TL
    Hematology; 2003 Feb; 8(1):27-33. PubMed ID: 12623424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.
    Gaziev D; Galimberti M; Lucarelli G; Polchi P; Giardini C; Angelucci E; Baronciani D; Sodani P; Erer B; Biagi MD; Andreani M; Agostinelli F; Donati M; Nesci S; Talevi N
    Bone Marrow Transplant; 2000 Apr; 25(8):815-21. PubMed ID: 10808201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.
    Castro-Malaspina H; Harris RE; Gajewski J; Ramsay N; Collins R; Dharan B; King R; Deeg HJ
    Blood; 2002 Mar; 99(6):1943-51. PubMed ID: 11877264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
    Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
    Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
    Phillips GL; Barnett MJ; Brain MC; Chan KW; Huebsch LB; Klingemann HG; Meharchand J; Reece DE; Rybka WB; Shepherd JD
    Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
    DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
    Hernández-Boluda JC; Marín P; Carreras E; Aguilar JL; Grañena A; Rozman C; Montserrat E
    Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.